Gapping up
In reaction to strong earnings/guidance: TIK +10.7%, OHGI +8.5%, BCOM +5.3%, (co's subsid posted earnings update), PLUG +2.2%, YOD +1%
M&A news: ERIC +1.6% (Friday rumors of acquisition by Cisco (CSCO); states recent partnership had no discussions of merger)
Select metals/mining stocks trading higher: AUY +2.7%, AEM +1.6%, SLW +1.5%, GDX +1%, BHP +0.7%, GLD +0.7%
Select oil/gas related names showing strength: RDS.A +1.2%, RIG +1.1%, BP +0.7%, CHK +0.5%, TOT +0.4%
Other news: NLST +21.5% (U.S. Federal Court of Appeals upheld the validity of all claims in the reexamination of U.S. Pat. No. 7,532,537 brought by Inphi (IPHI)), NVET +16.8% (reports results of NV-01 pivotal study in dogs; study met primary endpoint), BIOL +13.3% (Jack W. Schuler, ~20% active stake, discloses entry into standstill agreement), ARWR +7.4% (presents data showing robust sustained anti-viral effects with ARC-520 in Hepatitis B), FCEL +7.4% (still checking), GLPG +6.1% (still checking; rebounding pre-mkt following last week's declines), ARRY +5.5% (Array Biopharma and Pierre Fabre announces collaboration to develop and commercialize Array's late-stage novel oncology products, binimetinib and encorafenib), PLX +5.2% (files for $100 mln mixed securities shelf offering; also initiates a Phase III Clinical Trial for PRX-102 to treat Fabry Disease, following a successful end-of-phase II meeting with the FDA), NATH +3.6% ( increases the price range of its previously announced Dutch Auction tender offer), MBT +3.2% (cont strength), SODA +3.1% (CEO purchases 30k ordinary shares on the open market), CGIX +3% (Frigate Ventures discloses 6.5% passive stake in 13G filing), IBN +2.4% (outperformer in the Sensex today), SUNE +1.8% (profiled in Barrons), VIPS +1.7% (pre-mkt rebound after last week's declines)
Analyst comments: PRGO +1.8% (upgraded to Buy from Neutral at UBS), BUD +1.8% (upgraded to Outperform at Exane BNP Paribas ), NVDA +1% (upgraded to Buy from Hold at Canaccord Genuity ), ORCL +0.9% (added to Conviction Buy List at Goldman), AV +0.7% (upgraded to Buy at BofA/Merrill
)
In reaction to strong earnings/guidance: TIK +10.7%, OHGI +8.5%, BCOM +5.3%, (co's subsid posted earnings update), PLUG +2.2%, YOD +1%
M&A news: ERIC +1.6% (Friday rumors of acquisition by Cisco (CSCO); states recent partnership had no discussions of merger)
Select metals/mining stocks trading higher: AUY +2.7%, AEM +1.6%, SLW +1.5%, GDX +1%, BHP +0.7%, GLD +0.7%
Select oil/gas related names showing strength: RDS.A +1.2%, RIG +1.1%, BP +0.7%, CHK +0.5%, TOT +0.4%
Other news: NLST +21.5% (U.S. Federal Court of Appeals upheld the validity of all claims in the reexamination of U.S. Pat. No. 7,532,537 brought by Inphi (IPHI)), NVET +16.8% (reports results of NV-01 pivotal study in dogs; study met primary endpoint), BIOL +13.3% (Jack W. Schuler, ~20% active stake, discloses entry into standstill agreement), ARWR +7.4% (presents data showing robust sustained anti-viral effects with ARC-520 in Hepatitis B), FCEL +7.4% (still checking), GLPG +6.1% (still checking; rebounding pre-mkt following last week's declines), ARRY +5.5% (Array Biopharma and Pierre Fabre announces collaboration to develop and commercialize Array's late-stage novel oncology products, binimetinib and encorafenib), PLX +5.2% (files for $100 mln mixed securities shelf offering; also initiates a Phase III Clinical Trial for PRX-102 to treat Fabry Disease, following a successful end-of-phase II meeting with the FDA), NATH +3.6% ( increases the price range of its previously announced Dutch Auction tender offer), MBT +3.2% (cont strength), SODA +3.1% (CEO purchases 30k ordinary shares on the open market), CGIX +3% (Frigate Ventures discloses 6.5% passive stake in 13G filing), IBN +2.4% (outperformer in the Sensex today), SUNE +1.8% (profiled in Barrons), VIPS +1.7% (pre-mkt rebound after last week's declines)
Analyst comments: PRGO +1.8% (upgraded to Buy from Neutral at UBS), BUD +1.8% (upgraded to Outperform at Exane BNP Paribas ), NVDA +1% (upgraded to Buy from Hold at Canaccord Genuity ), ORCL +0.9% (added to Conviction Buy List at Goldman), AV +0.7% (upgraded to Buy at BofA/Merrill
)